Updated Guidelines for Treatment of von Willebrand Disease
The American Society of Hematology (ASH) has developed clinical practice guidelines for the diagnosis and management of von Willebrand Disease (VWD) in partnership with the International Society of Thrombosis and Haemostasis (ISTH), National Hemophilia Foundation (NHF), World Federation of Hemophilia (WFH), and the University of Kansas Medical Center. The guidelines were published on January 12, 2021, in Blood Advances.
VWD is the most common inherited bleeding disorder with wide variability in clinical phenotype. Arriving at an accurate diagnosis can be challenging due to variability in test accuracy, diagnostic thresholds, and access to specialty centers.
The publication of the two guidelines on diagnosis and management will be accompanied by clinical tools and educational resources to help patients, hematologists, and other healthcare providers understand and implement the recommendations.